CN Patent

CN114761010B — 喹唑啉衍生物或其盐的联用药物组合物及其用途

Assigned to Capital Pharmaceutical Holdings Beijing Co ltd · Expires 2024-04-16 · 2y expired

What this patent protects

本申请涉及用于治疗或预防乳腺癌的式(I)化合物(化学名称：N 6 ‑(1‑丙烯酰基氮杂环己烷‑4‑基)‑N 4 ‑(3‑氯‑4‑氟苯基)‑7‑甲氧基喹唑啉‑4,6‑二胺)或其可药用盐、式(I)化合物或其可药用盐与卡培他滨的联用药物组合物，以及所述联用药物组合物在治疗和预防乳腺癌中的用途。

USPTO Abstract

本申请涉及用于治疗或预防乳腺癌的式(I)化合物(化学名称：N 6 ‑(1‑丙烯酰基氮杂环己烷‑4‑基)‑N 4 ‑(3‑氯‑4‑氟苯基)‑7‑甲氧基喹唑啉‑4,6‑二胺)或其可药用盐、式(I)化合物或其可药用盐与卡培他滨的联用药物组合物，以及所述联用药物组合物在治疗和预防乳腺癌中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN114761010B
Jurisdiction
CN
Classification
—
Expires
2024-04-16
Drug substance claim
No
Drug product claim
No
Assignee
Capital Pharmaceutical Holdings Beijing Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.